

Mylan:

Q2 2018 Non-GAAP Reconciliations

August 8, 2018



Better Health
for a Better World[®]

Non-GAAP Financial Measures

This presentation includes the presentation and discussion of certain financial information that differs from what is reported under U.S. GAAP. These non-GAAP financial measures, including, but not limited to, adjusted gross margins, adjusted R&D as % of total revenues, adjusted SG&A as % of total revenues, adjusted earnings from operations, adjusted EBITDA, adjusted net earnings, adjusted EPS, adjusted net cash provided by operating activities, adjusted free cash flow, adjusted effective tax rate, adjusted segment profitability for North America and constant currency figures are presented in order to supplement investors' and other readers' understanding and assessment of the financial performance of Mylan N.V. ("Mylan" or the "Company"). In the Appendix, Mylan has provided reconciliations of such non-GAAP financial measures to the most directly comparable U.S. GAAP financial measures. Investors and other readers are encouraged to review the related U.S. GAAP financial measures and the reconciliations of the non-GAAP measures to their most directly comparable U.S. GAAP measures set forth below, and investors and other readers should consider non-GAAP measures only as supplements to, not as substitutes for or as superior measures to, the measures of financial performance prepared in accordance with U.S. GAAP.

2018 Guidance

Mylan is not providing forward looking guidance for U.S. GAAP reported financial measures or a quantitative reconciliation of forward-looking non-GAAP financial measures to the most directly comparable U.S. GAAP measure because it is unable to predict with reasonable certainty the ultimate outcome of certain significant items without unreasonable effort. These items include, but are not limited to, acquisition-related expenses including those related to the acquisition of Meda AB (publ), restructuring expenses, asset impairments, litigation settlements and other contingencies, including changes to contingent consideration and certain other gains or losses. These items are uncertain, depend on various factors, and could have a material impact on U.S. GAAP reported results for the guidance period.

Mylan N.V. and Subsidiaries
Reconciliation of Non-GAAP Financial Measures

(Unaudited; in millions)

| <i>(in millions, except per share amounts)</i> | Adjusted Net Earnings and Adjusted EPS | | | | | | | |
|--|---|----------------|----------------------------------|----------------|-------------------|---------------|-------------------|---------------|
| | Three Months Ended June 30, | | Six Months Ended June 30, | | | | | |
| | 2018 | 2017 | 2018 | 2017 | | | | |
| U.S. GAAP net earnings and U.S. GAAP EPS | \$ 37.5 | \$ 0.07 | \$297.0 | \$0.55 | \$ 124.6 | \$0.24 | \$ 363.4 | \$0.68 |
| Purchase accounting related amortization (primarily included in cost of sales) ^(a) | 430.3 | 355.0 | 853.7 | 704.2 | | | | |
| Litigation settlements and other contingencies, net | (46.4) | (50.0) | (30.2) | (41.0) | | | | |
| Interest expense (primarily clean energy investment financing and accretion of contingent consideration) | 9.2 | 13.6 | 18.9 | 26.9 | | | | |
| Clean energy investments pre-tax loss | 23.0 | 21.7 | 46.0 | 44.0 | | | | |
| Acquisition related costs (primarily included in SG&A and cost of sales) ^(b) | 10.2 | 19.0 | 12.5 | 45.0 | | | | |
| Restructuring related costs ^(c) | 76.1 | 16.2 | 121.5 | 39.3 | | | | |
| Other special items included in: | | | | | | | | |
| Cost of sales ^(d) | 64.0 | 14.6 | 74.0 | 26.9 | | | | |
| Research and development expense ^(e) | 50.5 | 9.7 | 97.1 | 74.8 | | | | |
| Selling, general and administrative expense ^(f) | 32.1 | 2.8 | 33.9 | 8.7 | | | | |
| Other expense, net ^(g) | 6.8 | (0.2) | 24.2 | 7.8 | | | | |
| Tax effect of the above items and other income tax related items | <u>(141.8)</u> | <u>(109.5)</u> | <u>(329.1)</u> | <u>(210.3)</u> | | | | |
| Adjusted net earnings and adjusted EPS | <u>\$551.5</u> | <u>\$ 1.07</u> | <u>\$589.9</u> | <u>\$1.10</u> | <u>\$ 1,047.1</u> | <u>\$2.03</u> | <u>\$ 1,089.7</u> | <u>\$2.03</u> |
| Weighted average diluted ordinary shares outstanding | <u>516.3</u> | <u>537.0</u> | <u>516.6</u> | <u>537.0</u> | | | | |

- (a) The increase in purchase accounting related amortization is primarily due to the increase in amortization expense as a result of the full impact of certain product rights acquisitions which occurred in 2017, the current year impact of the 2018 product rights acquisitions and the IPR&D impairment charges of \$42.0 million and \$72.0 million during the three and six months ended June 30, 2018, respectively.
- (b) Acquisition related costs incurred in 2017 and through the six months ended June 30, 2018 consist primarily of integration activities.
- (c) For the three months ended June 30, 2018, approximately \$41.0 million is included in cost of sales, \$11.8 million is included in R&D, and \$23.6 million is included in SG&A. For the six months ended June 30, 2018, approximately \$45.4 million is included in cost of sales, \$16.7 million is included in R&D, and \$59.7 million is included in SG&A. Refer to Note 17 Restructuring included in Part I, Item 1 of the Form 10-Q for additional information.
- (d) The three and six months ended June 30, 2018 increase relates primarily to approximately \$56.0 million of certain incremental manufacturing variances and site remediation expenses as a result of the activities at the Company's Morgantown facility.
- (e) R&D expense for the three months ended June 30, 2018 includes two non-refundable upfront payments totaling approximately \$30.5 million for development agreements entered into during the quarter, and the remaining expense relates to on-going collaboration agreements, including Momenta Pharmaceuticals, Inc. ("Momenta"). For the six months ended June 30, 2018, R&D expense includes \$73.5 million related to four non-refundable upfront payments for development agreements entered into during the current period. The remaining expense relates to the on-going collaboration agreements, including Momenta. R&D expense for the three months ended June 30, 2017 includes \$8.7 million related to Momenta collaboration expense. For the six months ended June 30, 2017, R&D expense includes an upfront expense of approximately \$50.0 million related to a joint development and marketing agreement for a respiratory product, \$14.5 million related to Momenta collaboration expense, and other similar smaller agreements.
- (f) Increase for the three and six months ended June 30, 2018 primarily related to bad debt expense of approximately \$26.5 million related to a specific business interruption event for one customer.
- (g) Primarily related to mark-to-market losses of investments in equity securities historically accounted for as available-for-sale securities and the cumulative realized gains on such investments.

Mylan N.V. and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Unaudited; in millions)
Net Earnings to Adjusted EBITDA

| | Three Months Ended | | Six Months Ended | |
|--|---------------------------|-------------|-------------------------|-------------|
| | June 30, | | June 30, | |
| | 2018 | 2017 | 2018 | 2017 |
| U.S. GAAP net earnings | \$ 37.5 | \$ 297.0 | \$ 124.6 | \$ 363.4 |
| Add adjustments: | | | | |
| Net contribution attributable to equity method investments | 22.9 | 21.7 | 46.0 | 54.9 |
| Income tax (benefit) provision | (18.8) | 27.7 | (95.4) | 32.9 |
| Interest expense | 139.2 | 136.3 | 270.9 | 274.5 |
| Depreciation and amortization | 501.9 | 421.2 | 1,000.4 | 836.7 |
| EBITDA | \$ 682.7 | \$ 903.9 | \$ 1,346.5 | \$ 1,562.4 |
| Add adjustments: | | | | |
| Share-based compensation expense | (0.8) | 18.9 | 20.6 | 42.0 |
| Litigation settlements and other contingencies, net | (46.4) | (50.0) | (30.2) | (41.0) |
| Restructuring & other special items | 231.1 | 58.1 | 343.6 | 180.1 |
| Adjusted EBITDA | \$ 866.6 | \$ 930.9 | \$ 1,680.5 | \$ 1,743.5 |

Mylan N.V. and Subsidiaries
Reconciliation of Non-GAAP Financial Measures

(Unaudited; in millions)

Total Revenues by Segment

| <i>(In millions)</i> | Three Months Ended June 30, | | | | | |
|--|--------------------------------------|-------------------|----------|---|--|--|
| | 2018 | 2017 | % Change | 2018 Currency Impact ⁽¹⁾ | 2018 Constant Currency Revenues | Constant Currency % Change ⁽²⁾ |
| Net sales | | | | | | |
| North America | \$ 1,000.8 | \$ 1,279.6 | (22)% | \$ (2.7) | \$ 998.1 | (22)% |
| Europe | 990.6 | 954.3 | 4 % | (68.4) | 922.2 | (3)% |
| Rest of World | 764.1 | 692.6 | 10 % | 6.6 | 770.7 | 11 % |
| Total net sales | <u>2,755.5</u> | <u>2,926.5</u> | (6)% | (64.5) | 2,691.0 | (8)% |
| Other revenues ⁽³⁾ | <u>52.8</u> | <u>35.7</u> | 48 % | (1.0) | 51.8 | 45 % |
| Consolidated total revenues ⁽⁴⁾ | <u>\$ 2,808.3</u> | <u>\$ 2,962.2</u> | (5)% | \$ (65.5) | \$ 2,742.8 | (7)% |
| | Six Months Ended June 30, | | | | | |
| <i>(In millions)</i> | 2018 | 2017 | % Change | 2018 Currency Impact ⁽¹⁾ | 2018 Constant Currency Revenues | Constant Currency % Change ⁽²⁾ |
| Net sales | | | | | | |
| North America | \$ 1,986.1 | \$ 2,494.5 | (20)% | \$ (5.8) | \$ 1,980.3 | (21)% |
| Europe | 2,029.0 | 1,846.3 | 10 % | (201.2) | 1,827.8 | (1)% |
| Rest of World | 1,390.8 | 1,273.1 | 9 % | (21.6) | 1,369.2 | 8 % |
| Total net sales | <u>5,405.9</u> | <u>5,613.9</u> | (4)% | (228.6) | 5,177.3 | (8)% |
| Other revenues ⁽³⁾ | <u>86.9</u> | <u>67.8</u> | 28 % | (2.9) | 84.0 | 24 % |
| Consolidated total revenues ⁽⁴⁾ | <u>\$ 5,492.8</u> | <u>\$ 5,681.7</u> | (3)% | \$ (231.5) | \$ 5,261.3 | (7)% |

(1) Currency impact is shown as unfavorable (favorable).

(2) The constant currency percentage change is derived by translating net sales or revenues for the current period at prior year comparative period exchange rates, and in doing so shows the percentage change from 2018 constant currency net sales or revenues to the corresponding amount in the prior year.

(3) For the three months ended June 30, 2018, other revenues in North America, Europe, and Rest of World were approximately \$42.5 million, \$2.9 million, and \$7.4 million, respectively. For the six months ended June 30, 2018, other revenues in North America, Europe, and Rest of World were approximately \$63.6 million, \$12.4 million, and \$10.9 million, respectively.

(4) Amounts exclude intersegment revenue that eliminates on a consolidated basis.

Mylan N.V. and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Unaudited; in millions)
Cost of Sales

| <i>(In millions)</i> | Three Months Ended June 30, | | Six Months Ended June 30, | |
|--|--------------------------------|------------|------------------------------|------------|
| | 2018 | 2017 | 2018 | 2017 |
| U.S. GAAP cost of sales | \$ 1,845.8 | \$ 1,736.8 | \$ 3,546.0 | \$ 3,371.3 |
| Deduct: | | | | |
| Purchase accounting amortization and other related items | (427.4) | (350.2) | (848.3) | (693.5) |
| Acquisition related items | (0.8) | (1.4) | (1.0) | (2.1) |
| Restructuring and related costs | (41.0) | (3.4) | (45.4) | (16.3) |
| Other special items | (64.0) | (14.6) | (74.0) | (26.9) |
| Adjusted cost of sales | \$ 1,312.6 | \$ 1,367.2 | \$ 2,577.3 | \$ 2,632.5 |
| Adjusted gross profit ^(a) | \$ 1,495.7 | \$ 1,595.0 | \$ 2,915.5 | \$ 3,049.2 |
| Adjusted gross margin ^(a) | 53 % | 54 % | 53 % | 54 % |

(a) U.S. GAAP gross profit is calculated as total revenues less U.S. GAAP cost of sales. U.S. GAAP gross margin is calculated as U.S. GAAP gross profit divided by total revenues. Adjusted gross profit is calculated as total revenues less adjusted cost of sales. Adjusted gross margin is calculated as adjusted gross profit divided by total revenues.

Mylan N.V. and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Unaudited; in millions)
R&D

| | Three Months Ended June 30, | | Six Months Ended June 30, | |
|--|--|-----------------|--------------------------------------|-----------------|
| | 2018 | 2017 | 2018 | 2017 |
| U.S. GAAP R&D | \$ 206.7 | \$ 181.1 | \$ 411.6 | \$ 398.6 |
| Deduct: | | | | |
| Acquisition related costs | (0.4) | (0.3) | (0.5) | (0.6) |
| Restructuring and related costs | (11.8) | (0.1) | (16.7) | (1.4) |
| Purchase accounting amortization and other related items | (0.1) | — | (0.1) | — |
| Other special items | (50.5) | (9.7) | (97.1) | (74.8) |
| Adjusted R&D | \$ 143.9 | \$ 171.0 | \$ 297.2 | \$ 321.8 |
| Adjusted R&D as % of total revenues | <u>5 %</u> | <u>6 %</u> | <u>5 %</u> | <u>6 %</u> |

Mylan N.V. and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Unaudited; in millions)
SG&A

| | Three Months Ended June 30, | | Six Months Ended June 30, | |
|--|--|-----------------|--------------------------------------|-------------------|
| | 2018 | 2017 | 2018 | 2017 |
| U.S. GAAP SG&A | \$ 623.3 | \$ 620.5 | \$ 1,230.8 | \$ 1,251.3 |
| Deduct: | | | | |
| Acquisition related costs | (9.1) | (17.5) | (11.1) | (41.5) |
| Restructuring related costs | (23.6) | (12.7) | (59.7) | (21.6) |
| Purchase accounting amortization and other related items | (2.9) | (4.9) | (5.3) | (5.1) |
| Other special items | (32.1) | (2.8) | (33.9) | (8.7) |
| Adjusted SG&A | <u>\$ 555.6</u> | <u>\$ 582.6</u> | <u>\$ 1,120.8</u> | <u>\$ 1,174.4</u> |
| Adjusted SG&A as % of total revenues | <u>20 %</u> | <u>20 %</u> | <u>20 %</u> | <u>21 %</u> |

Mylan N.V. and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Unaudited; in millions)
Total Operating Expenses

| | Three Months Ended June 30, | | Six Months Ended June 30, | |
|---|--|-----------------|--------------------------------------|-------------------|
| | 2018 | 2017 | 2018 | 2017 |
| U.S. GAAP total operating expenses | \$ 783.6 | \$ 751.6 | \$ 1,612.2 | \$ 1,608.9 |
| Add / (deduct): | | | | |
| Litigation settlements and other contingencies, net | 46.4 | 50.0 | 30.2 | 41.0 |
| R&D adjustments | (62.8) | (10.1) | (114.4) | (76.9) |
| SG&A adjustments | (67.7) | (37.9) | (110.0) | (77.0) |
| Adjusted total operating expenses | <u>\$ 699.5</u> | <u>\$ 753.6</u> | <u>\$ 1,418.0</u> | <u>\$ 1,496.0</u> |
| Adjusted earnings from operations ^(a) | <u>\$ 796.2</u> | <u>\$ 841.4</u> | <u>\$ 1,497.5</u> | <u>\$ 1,553.2</u> |

(a) U.S. GAAP earnings from operations is calculated as U.S. GAAP gross profit less U.S. GAAP total operating expenses. Adjusted earnings from operations is calculated as adjusted gross profit less adjusted total operating expenses.

Mylan N.V. and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Unaudited; in millions)
Interest Expense

| | Three Months Ended | | Six Months Ended | |
|--|---------------------------|-----------------|-------------------------|-----------------|
| | June 30, | | June 30, | |
| | 2018 | 2017 | 2018 | 2017 |
| U.S. GAAP interest expense | \$ 139.2 | \$ 136.3 | \$ 270.9 | \$ 274.5 |
| Deduct: | | | | |
| Interest expense related to clean energy investments | (2.1) | (3.1) | (4.4) | (6.4) |
| Accretion of contingent consideration liability | (5.5) | (8.6) | (11.0) | (16.7) |
| Acquisition related costs | — | — | — | (0.2) |
| Other special items | (1.6) | (1.8) | (3.5) | (3.6) |
| Adjusted interest expense | <u>\$ 130.0</u> | <u>\$ 122.8</u> | <u>\$ 252.0</u> | <u>\$ 247.6</u> |

Mylan N.V. and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Unaudited; in millions)
Other Expense

| | Three Months Ended June 30, | | Six Months Ended June 30, | |
|---|--|-----------------|--------------------------------------|------------------|
| | 2018 | 2017 | 2018 | 2017 |
| U.S. GAAP other expense, net | \$ 21.0 | \$ 12.8 | \$ 34.5 | \$ 30.7 |
| Add / (deduct): | | | | |
| Clean energy investments pre-tax income (loss) ^(a) | (23.0) | (21.7) | (46.0) | (44.0) |
| Purchase accounting related amortization | — | — | — | (5.7) |
| Acquisition related costs | — | — | — | (0.8) |
| Restructuring and related costs | 0.3 | — | 0.3 | 0.4 |
| Other items ^(b) | (6.8) | 0.2 | (24.2) | (7.8) |
| Adjusted other income | \$ (8.5) | \$ (8.7) | \$ (35.4) | \$ (27.2) |

(a) Adjustment represents exclusion of activity related to Mylan's clean energy investments, the activities of which qualify for income tax credits under section 45 of the U.S. Internal Revenue Code of 1986, as amended.

(b) Primarily related to mark-to-market losses of investments in equity securities historically accounted for as available-for-sale securities and the cumulative realized gains on such investments.

Mylan N.V. and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Unaudited; in millions)
Earnings Before Income Taxes and Income Tax Provision

| | Three Months Ended | | Six Months Ended | |
|---|---------------------------|-----------------|-------------------------|-------------------|
| | June 30, | | June 30, | |
| | 2018 | 2017 | 2018 | 2017 |
| U.S. GAAP earnings before income taxes | \$ 18.7 | \$ 324.7 | \$ 29.2 | \$ 396.3 |
| Total pre tax non-GAAP adjustments | 655.9 | 402.4 | 1,251.7 | 936.6 |
| Adjusted earnings before income taxes | <u>\$ 674.6</u> | <u>\$ 727.1</u> | <u>\$ 1,280.9</u> | <u>\$ 1,332.9</u> |
| | | | | |
| U.S. GAAP income tax (benefit) provision | \$ (18.8) | \$ 27.7 | \$ (95.4) | \$ 32.9 |
| Adjusted tax expense | 142.0 | 109.5 | 329.2 | 210.3 |
| Adjusted income tax provision | <u>\$ 123.2</u> | <u>\$ 137.2</u> | <u>\$ 233.8</u> | <u>\$ 243.2</u> |
| | | | | |
| Adjusted effective tax rate | <u>18.3%</u> | <u>18.9%</u> | <u>18.3%</u> | <u>18.2%</u> |

Mylan N.V. and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Unaudited; in millions)
Adjusted Net Cash Provided by Operating Activities

| | Three Months Ended | | Six Months Ended | |
|--|---------------------------|-----------------|-------------------------|-------------------|
| | June 30, | | June 30, | |
| | 2018 | 2017 | 2018 | 2017 |
| U.S. GAAP net cash provided by operating activities | \$ 430.2 | \$ 567.8 | \$ 1,052.0 | \$ 1,020.7 |
| Add: | | | | |
| Restructuring and related costs ^(a) | 95.9 | 34.3 | 127.4 | 89.5 |
| Financing related expense | 2.6 | — | 2.6 | — |
| Corporate contingencies | 110.2 | 32.5 | 110.2 | 32.5 |
| Acquisition related costs | 2.2 | 29.4 | 3.7 | 52.3 |
| R&D expense | 60.5 | — | 100.0 | 5.0 |
| Other | 5.0 | — | 5.0 | — |
| Adjusted net cash provided by operating activities | <u>\$ 706.6</u> | <u>\$ 664.0</u> | <u>\$ 1,400.9</u> | <u>\$ 1,200.0</u> |
| Deduct: | | | | |
| Capital expenditures | (45.2) | (50.9) | (75.9) | (109.3) |
| Adjusted free cash flow | <u>\$ 661.4</u> | <u>\$ 613.1</u> | <u>\$ 1,325.0</u> | <u>\$ 1,090.7</u> |

(a) For the three and six months ended June 30, 2018 includes approximately \$56.0 million of certain incremental manufacturing variances and site remediation expenses as a result of the activities at the Company's Morgantown facility.

Mylan N.V. and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Unaudited; in millions)
Net Earnings to Adjusted EBITDA

| | Three Months Ended | | | |
|--|-----------------------|----------------------|-------------------|------------------|
| | September 30, 2017 | December 31, 2017 | March 31, 2018 | June 30, 2018 |
| U.S. GAAP net earnings | \$ 88.3 | \$ 244.3 | \$ 87.1 | \$ 37.5 |
| Add adjustments: | | | | |
| Net contribution attributable to equity method investments | 22.4 | (19.2) | 23.1 | 22.9 |
| Income tax provision (benefit) | 91.3 | 82.8 | (76.6) | (18.8) |
| Interest expense | 131.8 | 128.3 | 131.7 | 139.2 |
| Depreciation and amortization | 443.1 | 526.0 | 498.5 | 501.9 |
| EBITDA | \$ 776.9 | \$ 962.2 | \$ 663.8 | \$ 682.7 |
| Add adjustments: | | | | |
| Share-based compensation expense | 22.2 | 10.5 | 21.4 | (0.8) |
| Litigation settlements and other contingencies, net | 15.2 | 12.7 | 16.2 | (46.4) |
| Restructuring & other special items | 109.5 | 138.2 | 112.5 | 231.1 |
| Adjusted EBITDA | \$ 923.8 | \$ 1,123.6 | \$ 813.9 | \$ 866.6 |

Mylan N.V. and Subsidiaries
Reconciliation of Non-GAAP Financial Measures

(Unaudited; in millions)

**June 30, 2018 Notional Debt to Twelve Months Ended June 30, 2018 Mylan N.V. Adjusted EBITDA
as calculated under our Credit Agreements (“Credit Agreement Adjusted EBITDA”) Leverage Ratio**

The stated non-GAAP financial measure June 30, 2018 notional debt to twelve months ended June 30, 2018 Credit Agreement Adjusted EBITDA leverage ratio is based on the sum of (i) Mylan’s adjusted EBITDA for the quarters ended September 30, 2017, December 31, 2017, March 31, 2018 and June 30, 2018 and (ii) certain adjustments permitted to be included in Credit Agreement Adjusted EBITDA as of June 30, 2018 pursuant to the Company’s revolving credit facility dated as of November 22, 2016 (as amended, supplemented or otherwise modified from time to time), among the Company, certain affiliates and subsidiaries of the Company from time to time party thereto as guarantors, each lender from time to time party thereto and Bank of America, N.A., as administrative agent and the Company’s term loan credit facility dated as of November 22, 2016 (as amended, supplemented or otherwise modified from time to time), among the Company, certain affiliates and subsidiaries of the Company from time to time party thereto as guarantors, each lender from time to time party thereto and Goldman Sachs Bank USA, as administrative agent (together, the "Credit Agreements") as compared to Mylan’s June 30, 2018 total debt and other current obligations at notional amounts.

| | Three Months Ended | | | | Twelve |
|--|-----------------------|----------------------|-------------------|------------------|----------------------------------|
| | September 30, 2017 | December 31, 2017 | March 31, 2018 | June 30, 2018 | Months Ended June 30, 2018 |
| Mylan N.V. Adjusted EBITDA | \$ 923.8 | \$ 1,123.6 | \$ 813.9 | \$ 866.6 | \$ 3,727.9 |
| Add: other adjustments including estimated synergies | | | | | 46.3 |
| Credit Agreement Adjusted EBITDA | | | | | <u>\$ 3,774.2</u> |
| Reported debt balances: | | | | | |
| Long-term debt, including current portion | | | | | \$ 14,455.8 |
| Short-term borrowings and other current obligations | | | | | 285.4 |
| Total | | | | | <u>\$ 14,741.2</u> |
| Add / (deduct): | | | | | |
| Net discount on various debt issuances | | | | | 39.3 |
| Deferred financing fees | | | | | 81.6 |
| Fair value of hedged debt | | | | | 6.8 |
| Total debt at notional amounts | | | | | <u>\$ 14,868.9</u> |

Notional debt to Credit Agreement Adjusted EBITDA Leverage Ratio

3.9



Better Health
for a Better World[®]